Repaglinide | Novonorm | Novo Nordisk, Denmark | Buy Anti Diabetic Drugs | Buy Novonorm | Anti Hyperglycemic Drug | Health Care

General information:

Manufacturer: Novo Nordisk, Denmark
Substance: Repaglinide
Pack: 30 tabs (2mg/tab)

Repaglinide is indicated in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus(NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reductionand exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patientswho are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation tomeals.

Therapeutic actions:
Repaglinide is a novel short-acting oral secretagogue. Repaglinide lowers the blood glucose levelsacutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning ?-cells in the pancreatic islets.
Repaglinide closes ATP-dependent potassium channels in the ?-cell membrane via a target proteindifferent from other secretagogues. This depolarises the ?-cell and leads to an opening of the calciumchannels. The resulting increased calcium influx induces insulin secretion from the ?-cell.
In Type 2 diabetic patients, the insulinotropic response to a meal occurred within 30 minutes after anoral dose of repaglinide. This resulted in a blood glucose-lowering effect throughout the meal period.
The elevated insulin levels did not persist beyond the time of the meal challenge. Plasma repaglinidelevels decreased rapidly, and low drug concentrations were seen in the plasma of Type 2 diabetic patients4 hours post-administration.
A dose-dependent decrease in blood glucose was demonstrated in Type 2 diabetic patients whenadministered in doses from 0.5 to 4 mg repaglinide.Clinical study results have shown that repaglinide is optimally dosed in relation to main meals(preprandial dosing).
Doses are usually taken within 15 minutes of the meal, but the time may vary from immediatelypreceding the meal to as long as 30 minutes before the meal.

Indications
Repaglinide is indicated in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus(NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reductionand exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patientswho are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation tomeals.

Price: 39.00 USD

Out of stock

Old Price: 49.00 USD

Back